Articles On Dimerix (ASX:DXB)

Stockhead’s Tylah Tully previews the 2026 ahead for  Dimerix (ASX:DXB) and recaps the goals the company achieved throughout 2025. Tune in to hear all the details.   This video was developed in collaboration with Dimerix, a Stockhead adverti...

Will Actinogen’s Xanamia trial prove a bigger hit than ABBA, or is it the company’s Waterloo? Upbeat Mach 7 licks its wounds after contract loss Neurizon and Heramed go to the well Alzheimer’s disease drug hopeful Actinogen Medical (ASX:A...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to the soaring highlights and cratering lowlights.   As usual we adopt the user-friendly A to Z format. If only drug, device and diagnos...

In a tight race, drug developer Nyrada so far is this year’s star performer with almost an eightfold gain Diagnostic house Lumos and imagers Artrya and 4D Medical also have run a good race, with their US plans unfolding to script Nyrada ch...

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto...

ASX green across the board, up 0.91% Materials and energy lead gains Broad-based market rally with 142 stocks higher   Gold hits new all-time high The ASX 200 started the shorter pre-Christmas week with a bang, up 0.91% or 78.5 points. Go...

Host Tylah Tully sits down with biopharmaceutical Dimerix (ASX:DXB) CEO and managing director Dr Nina Webster to explore how biotech companies can align R&D with commercial strategy from day one. Dr Webster explains why starting with th...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Recruitment successfully completed in Dimerix’ ACTION3 Phase 3 clinical trial[1], w...

Recruitment complete in Dimerix’s ACTION3 phase III clinical trial of DMX-200 in rare kidney disease focal segmental glomerulosclerosis The global trial has recruited and dosed its target 286th adult patient with 69 patients already comple...

In a pre-Christmas rush, biotechs report a flurry of clinical activity Radiopharm shares surge up to 22% on strong brain-imaging results Morgans says Sigma Health and EBOS Group shares are just the prescription for the Christmas hamper  ...

Highlights Major Australian leaders show sustained downward price pressure Select growth and technology names face renewed selling pressure A handful of emerging resources and healthcare stocks still trend higher Austr...

With over half the world’s population, the Asia-Pacific region looms as a major growth opportunity for Dimerix Shift in development pathway for pharmaceuticals seeking approval in major Asia-Pacific markets increases opportunity Dimerix ha...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX health sector fell 1.8% for the week, while broader market dropped 3.86% in the same period  FDA confirms Animal Rule and PRV potential for Island Pharmaceutical’s Galidesivir in Marburg Clever Culture identifies more than $45 million...

ASX climbs +0.23% before falling -0.25% Losses in banks, utilities, info tech undercut recovery Energy, materials, real estate mount resistance Markets wobble into red The ASX 200 obviously hasn’t quite recovered from the beating it took...

Seventh Independent Data Monitoring Committee review completed for Dimerix’s ACTION3 phase III study Committee recommends study of DMX-200 in kidney disease Focal Segmental Glomerulosclerosis continues unchanged Next scheduled meeting of I...

Strong clinical data can help biotechs secure lucrative licensing and partnership deals  Dimerix has four licensing deals for lead drug DMX-200 in rare kidney disease Platinum’s Global Health Sciences Fund manager Dr Bianca Ogden notes se...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

ASX retreats from session highs of +0.63pc to climb +0.30pc Gold and silver stocks recover from recent sell down NAB losses undercut broader gains   Precious metals get a polish The ASX 200 has bounced after closing at a three-week low ye...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

CSL watchers slash their valuations, yet retain faith in an eventual turnaround Medibank Private investors should Live Better now Dimerix’s trial plans are on track   CSL (ASX:CSL) analysts haven’t exactly given up on the stock following...

ASX closes at new high of 9094 points, up 0.7pc Broad momentum across sectors with 10 of 11 higher US-Australian critical mineral deals fuel more resource stock gains   ASX roars to new highs on US-Australia rare earths deal The ASX 200 s...

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode, Nadine chats with Dimerix  Managing Director Nina Webster.     Dimerix is a clinical-stage biopharmaceuti...

ASX 200 closes 0.13% lower on Friday, despite eight of 11 sectors higher  Tech sector leads gains while resource stocks weigh heavily Trigg Minerals continues to progress its proposed US Nasdaq listing    The ASX 200 ended the week lower...

ASX health sector moved up 1.30% for the week, while broader market inched up 0.12% This week: PainChek’s groundbreaking digital app scored coveted FDA De Novo clearance; The FDA lifted a clinical hold on Neurizon’s lead drug candidate for...

Stockhead’s Fraser Palamara catches up with Nina Webster, Managing Director at Dimerix (ASX:DXB), where she talks through the final data that has been released from the company’s recent collaboration with PARASOL, reinforcing the endpoints...

Final data analysis by the PARASOL collaboration with Dimerix generally consistent with broader analysis of FSGS patient data in 2024 Potential relationship was observed between proteinuria at 12 months and subsequent risk of kidney failur...

ASX down 9 points as AI jitters and profit taking set in Healthcare, materials sectors limit losses with some solid gains PainChek and Neurotech grab headlines with FDA wins; Dimerix also gains on strong news Glencore Mt Isa smelter bailed...

Dimerix (ASX: DXB) has received final data analysis from the international PARASOL collaboration that reinforces support for proteinuria-based endpoints in its pivotal Phase 3 Action3 study on DMX-200 for the treatment of kidney disease. Th...

PainChek can now tackle the US$100 million US aged-care market – while other geographies beckon Trivarx shares leap 9% on depression detection trial results Dimerix gets more assurances on using surrogate endpoints in its pivotal kidney t...

ASX closes 0.16% lower with nine of the 11 sectors in the red; materials led gainers; energy was leader of the laggards RBA keeps rates on hold at 3.6%, citing concerns inflation in the September quarter may be higher than expected Embedde...

Dimerix secures orphan drug designation for DMX-200 in Focal Segmental Glomerulosclerosis in Japan ACTION3 phase III clinical trial currently recruiting in Japan to support potential marketing approval in country FUSO Pharmaceutical Indust...

After a strategy revamp, Noxopharm is targeting inflammatory diseases – lupus in particular Affecting five million people, lupus has proved a tricky disease to tackle The company is pondering a phase II trial, most likely in skin lupus No...

Pitt Street Research says Imagion is significantly undervalued and sits around 75-80% below target range of 12.3 to 14.9 cents per share Research house sees further upside if MagSense imaging agent tech progresses to commercialisation in a...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Dimerix boss Dr Nina Webster to join Imagion Biosystems as non-executive director Webster has extensive experience with ASX healthcare companies and is also non-executive chair of SYNthesis BioVentures Appointment comes as Imagion prepares...

Ignite Partners is bringing the buzz to Hong Kong with a two-day power event packed with dynamic one-on-ones between top CEOs and hand-picked investors. The Grand Ballroom, 1 Harbour Road, Wan Chai, Hong Kong 15 – 16 October 2025 Pre-ar...

Morgans’ Scott Power describes mood at Bioshares Biotech Summit as “markedly more upbeat than prior years” with signs of a rotation back to ASX healthcare sector Power highlights nine ASX healthcare companies from summit with clear near-te...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights: ASX 200 trims early losses as sectors rebound Viva Energy under pressure after first-half update Lithium and uranium stocks show mixed reactions The ASX 200 began Tuesday’s session in the red, touching earl...

Prescient at critical stage of development with phase 2a trial underway for PTX-100 PTX-100 granted orphan drug and fast track designations by the US FDA, unlocking benefits Focus on advancing PTX-100 to potential registrational phase 2b t...

The S&P/ASX 200 Index (ASX: XJO) is having a positive start to the week. At the time of writing, the benchmark index is up 0.25% to 8,689.1 points. Four ASX shares that are rising more than most today are listed below. Here's why they a...

Highlights: Dimerix gains on milestone-rich licensing agreement Newmont lifts after delivering strong quarterly performance Titomic jumps following a successful capital raise As the broader S&P/ASX 200 index trades...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and on track to record a disappointing decline. At the time of writing, the benchmark index is down 0.5% to 8,664.4 points. Four ASX shares that are not letting that ho...

S&P/ASX 200 Index (ASX: XJO) gold stock Newmont Corp (ASX: NEM) is charging higher today. Newmont shares closed yesterday trading for $91.88. In morning trade on Friday, shares are changing hands for $96.01 apiece, up 4.5%. This sees Ne...

On Friday the 13th of December last year, Percheron Therapeutics (ASX:PER)  CEO Dr James Garner awaited the top-line results of the phase IIb Duchenne muscular dystrophy trial from his Brisbane lounge room. The company’s clinical developmen...

 Nanosonics has launched tweaked versions of its Trophon medical probe steriliser Amplia shares soar a further 36% on pancreatic cancer promise Dimerix looks to broaden its repertoire     Nanosonics (ASX:NAN) has launched updated iteratio...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

With the FDA’s blessing, Dimerix will use phase III trial endpoints that could lead to accelerated approval for its kidney disease drug Dimerix is confident of phase III success because an expert ‘peek’ at the blinded data shows it’s on th...